Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2024

Open Access 01-12-2024 | Tuberculosis | Study protocol

Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial

Authors: Phiona E. Namale, Linda Boloko, Marcia Vermeulen, Kate A. Haigh, Fortuna Bagula, Alexis Maseko, Bianca Sossen, Scott Lee-Jones, Yoliswa Msomi, Helen McIlleron, Ayanda Trevor Mnguni, Thomas Crede, Patryk Szymanski, Jonathan Naude, Sakeena Ebrahim, Yakoob Vallie, Muhammed Shiraz Moosa, Ismail Bandeker, Shakeel Hoosain, Mark P. Nicol, Nazlee Samodien, Chad Centner, Wentzel Dowling, Paolo Denti, Freedom Gumedze, Francesca Little, Arifa Parker, Brendon Price, Denzil Schietekat, Bryony Simmons, Andrew Hill, Robert J. Wilkinson, Ida Oliphant, Siphokazi Hlungulu, Ivy Apolisi, Monica Toleni, Zimkhitha Asare, Mkanyiseli Kenneth Mpalali, Erica Boshoff, Denise Prinsloo, Francisco Lakay, Abulele Bekiswa, Amanda Jackson, Ashleigh Barnes, Ryan Johnson, Sean Wasserman, Gary Maartens, David Barr, Charlotte Schutz, Graeme Meintjes

Published in: Trials | Issue 1/2024

Login to get access

Abstract

Background

HIV-associated tuberculosis (TB) contributes disproportionately to global tuberculosis mortality. Patients hospitalised at the time of the diagnosis of HIV-associated disseminated TB are typically severely ill and have a high mortality risk despite initiation of tuberculosis treatment. The objective of the study is to assess the safety and efficacy of both intensified TB treatment (high dose rifampicin plus levofloxacin) and immunomodulation with corticosteroids as interventions to reduce early mortality in hospitalised patients with HIV-associated disseminated TB.

Methods

This is a phase III randomised controlled superiority trial, evaluating two interventions in a 2 × 2 factorial design: (1) high dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days versus standard tuberculosis treatment and (2) adjunctive corticosteroids (prednisone 1.5 mg/kg/day) versus identical placebo for the first 14 days of TB treatment. The study population is HIV-positive patients diagnosed with disseminated TB (defined as being positive by at least one of the following assays: urine Alere LAM, urine Xpert MTB/RIF Ultra or blood Xpert MTB/RIF Ultra) during a hospital admission. The primary endpoint is all-cause mortality at 12 weeks comparing, first, patients receiving intensified TB treatment to standard of care and, second, patients receiving corticosteroids to those receiving placebo. Analysis of the primary endpoint will be by intention to treat. Secondary endpoints include all-cause mortality at 2 and 24 weeks. Safety and tolerability endpoints include hepatoxicity evaluations and corticosteroid-related adverse events.

Discussion

Disseminated TB is characterised by a high mycobacterial load and patients are often critically ill at presentation, with features of sepsis, which carries a high mortality risk. Interventions that reduce this high mycobacterial load or modulate associated immune activation could potentially reduce mortality. If found to be safe and effective, the interventions being evaluated in this trial could be easily implemented in clinical practice.

Trial registration

ClinicalTrials.gov NCT04951986. Registered on 7 July 2021
Appendix
Available only for authorised users
Literature
1.
Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.PubMedPubMedCentralCrossRef
2.
Bigna JJR, Noubiap JJN, Agbor AA, Plottel CS, Billong SC, Ayong APR, Koulla-Shiro S. Early mortality during initial treatment of tuberculosis in patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: an 8-year retrospective cohort study (2006-2013). PLoS One. 2015;10(7):e0132394.PubMedPubMedCentralCrossRef
3.
Subbarao S, Wilkinson KA, Van Halsema CL, Rao SS, Boyles T, Utay NS, et al. Raised venous lactate and markers of intestinal translocation are associated with mortality among in-patients with HIV-associated TB in rural South Africa. J Acquir Immune Defic Syndr. 2015;70(4):406.PubMedPubMedCentralCrossRef
4.
Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, et al. Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. PLoS Med. 2019;16(7):e1002840.PubMedPubMedCentralCrossRef
5.
Kyeyune R, den Boon S, Cattamanchi A, Davis JL, Worodria W, Yoo SD, Huang L. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr. 2010;55(4):446.PubMedPubMedCentralCrossRef
6.
Gupta-Wright A, Fielding K, Wilson D, van Oosterhout JJ, Grint D, Mwandumba HC, et al. Tuberculosis in hospitalized patients with human immunodeficiency virus: clinical characteristics, mortality, and implications from the rapid urine-based screening for tuberculosis to reduce AIDS related mortality in hospitalized patients in Africa. Clin Infect Dis. 2020;71(10):2618–26.PubMedCrossRef
7.
Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987–2002.PubMedCrossRef
8.
Boloko L, Schutz C, Sibiya N, Balfour A, Ward A, Shey M, et al. Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study. Lancet Microbe. 2022;3(7):e521-ee32.PubMedPubMedCentralCrossRef
9.
Barr DA, Schutz C, Balfour A, Shey M, Kamariza M, Bertozzi CR, et al. Serial measurement of M. tuberculosis in blood from critically-ill patients with HIV-associated tuberculosis. EBioMedicine. 2022;78:103949.PubMedPubMedCentralCrossRef
10.
Jacob ST, Pavlinac PB, Nakiyingi L, Banura P, Baeten JM, Morgan K, et al. Mycobacterium tuberculosis bacteremia in a cohort of HIV-infected patients hospitalized with severe sepsis in Uganda–high frequency, low clinical sand derivation of a clinical prediction score. PloS One. 2013;8(8):e70305.PubMedPubMedCentralCrossRef
11.
Andrews B, Semler MW, Muchemwa L, Kelly P, Lakhi S, Heimburger DC, et al. Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: a randomized clinical trial. Jama. 2017;318(13):1233–40.PubMedPubMedCentralCrossRef
12.
13.
Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49.PubMedPubMedCentralCrossRef
14.
Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, et al. Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis. Antimicrob Agents Chemother. 2018;62(12):e01014–8.PubMedPubMedCentralCrossRef
15.
Te Brake LH, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PP, et al. Increased bactericidal activity but dose-limiting intolerability at 50 mg· kg− 1 rifampicin. Eur Respir J. 2021;58(1).
16.
Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses. Clin Pharmacol Ther. 2018;103(4):674–83.PubMedCrossRef
17.
Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, Denti P. Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction. Antimicrob Agents Chemother. 2016;60(1):487–94.PubMedCrossRef
18.
Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–24.PubMedPubMedCentralCrossRef
19.
Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis. 1985;131(3):352–6.PubMed
20.
Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995;39(6):1341–4.PubMedPubMedCentralCrossRef
21.
Yew WW, Kwan SY-L, Ma WK, Khin MA, Chan PY. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother. 1990;26(2):227–36.PubMedCrossRef
22.
Yew W, Piddock L, Li M, Lyon D, Chan C, Cheng A. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother. 1994;34(3):343–51.PubMedCrossRef
23.
Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003;168(11):1342–5.PubMedCrossRef
24.
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98.PubMedCrossRef
25.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87.PubMedPubMedCentralCrossRef
26.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–608.PubMedPubMedCentralCrossRef
27.
Jindani A, Borgulya G, de Patino IW, Gonzales T, de Fernandes RA, Shrestha B, et al. A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20(6):832–8.PubMedCrossRef
28.
Gillespie S, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999;44(3):393–5.PubMedCrossRef
29.
Cremades R, Rodríguez JC, García-Pachón E, Galiana A, Ruiz-García M, López P, Royo G. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother. 2011;66(10):2281–3.PubMedCrossRef
30.
Dorman SE, Nahid P, Kurbatova EV, Phillips PP, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705–18.PubMedPubMedCentralCrossRef
31.
Nijland H, Ruslami R, Suroto AJ, Burger D, Alisjahbana B, Van Crevel R, Aarnoutse RJ. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45(8):1001–7.PubMedCrossRef
32.
Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, et al. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. J Antimicrob Chemother. 2017;72(5):1441–9.PubMedPubMedCentralCrossRef
33.
Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004;44(5):464–73.PubMedCrossRef
34.
FDA U. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. FDA Drug Safety Communication; 2018. p. 2020.
35.
Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology. 2015;85(15):1332–41.PubMedCrossRef
36.
Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–30.PubMedPubMedCentralCrossRef
37.
Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, et al. Randomized placebo-controlled trial of prednisone for paradoxical TB-associated immune reconstitution inflammatory syndrome. AIDS (London, England). 2010;24(15):2381.PubMedPubMedCentralCrossRef
38.
Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4.
39.
Wiysonge CS, Ntsekhe M, Thabane L, Volmink J, Majombozi D, Gumedze F, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017;9.
40.
Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915–25.PubMedCrossRef
41.
Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. In: Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2017.
42.
Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015;12.
43.
Dequin P-F, Meziani F, Quenot J-P, Kamel T, Ricard J-D, Badie J, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931–41.PubMedCrossRef
44.
45.
Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23(6):597–602.PubMedCrossRef
46.
Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;4.
47.
Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323(21):1451–7.PubMedCrossRef
48.
Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count< 200 cells/μL and virologic suppression: a systematic review. PloS one. 2011;6(12):e28570.PubMedPubMedCentralCrossRef
49.
Schutz C, Davis AG, Sossen B, Lai RP, Ntsekhe M, Harley YX, Wilkinson RJ. Corticosteroids as an adjunct to tuberculosis therapy. Expert Rev Respir Med. 2018;12(10):881–91.PubMedPubMedCentralCrossRef
50.
Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis. 1997;25(4):872–87.PubMedCrossRef
51.
Pletz MW, De Roux A, Roth A, Neumann K-H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother. 2004;48(3):780–2.PubMedPubMedCentralCrossRef
52.
Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183(4):968–81 e7.PubMedPubMedCentralCrossRef
53.
54.
Group RC. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.CrossRef
55.
56.
Mnguni AT, Schietekat D, Ebrahim N, Sonday N, Boliter N, Schrueder N, Gabriels S, Sigwadhi LN, Zemlin AE, Chapanduka ZC, Ngah V. The clinical and epidemiological characteristics of a series of patients living with HIV admitted for COVID-19 in a district hospital. BMC Infect Dis. 2023;23(1):123.
57.
Organization WH, Initiative ST. Treatment of tuberculosis: guidelines. World Health Organization; 2010.
58.
59.
Wasserman S, Davis A, Stek C, Chirehwa M, Botha S, Daroowala R, et al. Plasma pharmacokinetics of high-dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial. Antimicrob Agents Chemother. 2021;65(8):e00140–e00121.PubMedPubMedCentralCrossRef
60.
Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011;55(9):4122–7.PubMedPubMedCentralCrossRef
61.
Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008;177(7):680–5.PubMedPubMedCentralCrossRef
62.
Diacon A, Patientia R, Venter A, Van Helden P, Smith P, McIlleron H, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51(8):2994–6.PubMedPubMedCentralCrossRef
63.
McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56(6):3232–8.PubMedPubMedCentralCrossRef
64.
Court R, Chirehwa MT, Wiesner L, Wright B, Smythe W, Kramer N, McIlleron H. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Int J Tuberc Lung Dis. 2018;22(5):537–43.PubMedPubMedCentralCrossRef
65.
66.
Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2006;43(1):42–6.PubMedCrossRef
67.
Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–23.PubMedPubMedCentralCrossRef
68.
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52.PubMedCrossRef
69.
Rizvi I, Malhotra HS, Garg RK, Kumar N, Uniyal R, Pandey S. Fluoroquinolones in the management of tuberculous meningitis: systematic review and meta-analysis. J Infect. 2018;77(4):261–75.PubMedCrossRef
70.
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819–50.PubMedCrossRef
71.
Waitt C, Squire S. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2011;15(7):871–85.PubMedCrossRef
72.
Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One. 2010;5(12):e15241.PubMedPubMedCentralCrossRef
73.
Cresswell FV, Ellis J, Kagimu E, Bangdiwala AS, Okirwoth M, Mugumya G, et al. Standardized urine-based tuberculosis (TB) screening with TB-lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan adults with advanced human immunodeficiency virus disease and suspected meningitis. In: Open forum infectious diseases. Oxford University Press US; 2020.
74.
Atherton RR, Cresswell FV, Ellis J, Skipper C, Tadeo KK, Mugumya G, et al. Detection of Mycobacterium tuberculosis in urine by Xpert MTB/RIF Ultra: a useful adjunctive diagnostic tool in HIV-associated tuberculosis. Int J Infect Dis. 2018;75:92–4.PubMedPubMedCentralCrossRef
75.
Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G. Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. Int J Infect Dis. 2018;75:67–73.PubMedPubMedCentralCrossRef
76.
Fiorentino M, Nishimwe M, Protopopescu C, Iwuji C, Okesola N, Spire B, et al. Early ART initiation improves HIV status disclosure and social support in people living with HIV, linked to care within a universal test and treat program in rural South Africa (ANRS 12249 TasP Trial). AIDS Behavior. 2021;25:1306–22.PubMedCrossRef
77.
Girum T, Yasin F, Wasie A, Shumbej T, Bekele F, Zeleke B. The effect of “universal test and treat” program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia. AIDS Res Ther. 2020;17(1):1–9.CrossRef
78.
Lanoix J-P, Chaisson RE, Nuermberger EL. Shortening tuberculosis treatment with fluoroquinolones: lost in translation? Clin Infect Dis. 2016;62(4):484–90.PubMed
79.
Williams KJ, Duncan K. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr Mol Med. 2007;7(3):297–307.PubMedCrossRef
80.
Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006;10(6):605–12.PubMed
Metadata
Title
Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial
Authors
Phiona E. Namale
Linda Boloko
Marcia Vermeulen
Kate A. Haigh
Fortuna Bagula
Alexis Maseko
Bianca Sossen
Scott Lee-Jones
Yoliswa Msomi
Helen McIlleron
Ayanda Trevor Mnguni
Thomas Crede
Patryk Szymanski
Jonathan Naude
Sakeena Ebrahim
Yakoob Vallie
Muhammed Shiraz Moosa
Ismail Bandeker
Shakeel Hoosain
Mark P. Nicol
Nazlee Samodien
Chad Centner
Wentzel Dowling
Paolo Denti
Freedom Gumedze
Francesca Little
Arifa Parker
Brendon Price
Denzil Schietekat
Bryony Simmons
Andrew Hill
Robert J. Wilkinson
Ida Oliphant
Siphokazi Hlungulu
Ivy Apolisi
Monica Toleni
Zimkhitha Asare
Mkanyiseli Kenneth Mpalali
Erica Boshoff
Denise Prinsloo
Francisco Lakay
Abulele Bekiswa
Amanda Jackson
Ashleigh Barnes
Ryan Johnson
Sean Wasserman
Gary Maartens
David Barr
Charlotte Schutz
Graeme Meintjes
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Trials / Issue 1/2024
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-024-08119-4

Other articles of this Issue 1/2024

Trials 1/2024 Go to the issue

Study protocol

A physiotherapy group exercise and self-management approach to improve physical activity in people with mild-moderate Parkinson’s disease: a randomized controlled trial

Study protocol

Cost-effectiveness and cost-utility of the ball-and-socket trapeziometacarpal prosthesis compared to trapeziectomy and ligament reconstruction: study protocol for a randomized controlled clinical trial

Study protocol

Mean Arterial Pressure (MAP) Trial: study protocol for a multicentre, randomized, controlled trial to compare three different strategies of mean arterial pressure management during cardiopulmonary bypass

Study protocol

Study protocol: a core outcome set for perioperative exercise clinical effectiveness trials for lung cancer patients

Study protocol

Hypotension prediction index guided goal-directed therapy to reduce postoperative acute kidney injury during major abdominal surgery: study protocol for a multicenter randomized controlled clinical trial

Study protocol

Transcranial alternating current stimulation improves quality of life in Parkinson’s disease: study protocol for a randomized, double-blind, controlled trial